Geron | Working to change the course of blood cancers
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives.
Geron Corporation - Geron Announces FDA Approval of …
2024年6月6日 · Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration. Geron aims to ensure broad access to RYTELO for eligible patients.
FDA approves imetelstat for low- to intermediate-1 risk …
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk...
Geron finally brings a drug to market as FDA clears Rytelo
3 天之前 · More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.
Geron Corporation - Investors & Media
2025年3月19日 · Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
生物制药公司Geron端粒酶抑制剂RYTELO™获FDA批准，用于治疗 …
2024年6月7日 · FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 ...
Geron Corporation - Geron Announces European Commission …
2025年3月11日 · Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with ...
Geron Announces European Commission Approval of RYTELO® …
2025年3月11日 · FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...
FDA Approves Geron's First Commercial Drug, Competes With …
2024年6月7日 · On Thursday, the FDA approved Geron Corporation's (NASDAQ: GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
三十年磨一剑：调控生命时钟，全球首创端粒酶抑制剂上市 注：本 …
2024年9月18日 · 药融云数据显示：2024年6月6日，美国生物制药公司Geron Corporation（杰龙）宣布其开发的First-in-Class端粒酶抑制剂RYTELO（Imetelstat）获得FDA批准用于治疗低至中度-1风险骨髓增生异常综合征（MDS）成年患者的输血依赖性（TD）贫血，这些患者在8周内需要输 …